Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug may reduce insulin shots for young diabetes patients

NCT ID NCT07088068

Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 9 times

Summary

This study tests a drug called teplizumab in people aged 1 to 25 who were recently diagnosed with type 1 diabetes. The goal is to see if teplizumab can help control blood sugar and reduce the need for insulin at mealtimes. Participants will receive either teplizumab or a placebo through an IV, and their progress will be tracked for 52 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 723 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants are eligible to be included in the study only if all of the following criteria apply: * Participant must be 1 to 25 years of age inclusive, at the time of signing the informed consent. * Participants diagnosed with T1D Stage 3 according to American Diabetes Association 2025 criteria * Participants able to be randomized and initiate study drug within 8 weeks (56 days) of the Stage 3 T1D diagnosis * Participants must be positive for at least one T1D autoantibody at screening: * Glutamic acid decarboxylase (GAD-65), * Insulinoma Antigen-2 (IA-2), * Zinc-transporter 8 (ZnT8), or * Insulin (if obtained not later than 14 days after exogenous insulin therapy initiation). * Islet cell cytoplasmic autoantibodies (ICAs) * Have random C-peptide level ≥0.2 nmol/L obtained at screening * Enter Inclusion Criteria Sex * Both male and female participants are eligible. * Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * A female participant is eligible to participate if she is not pregnant, and one of the following conditions applies: * Is a woman of nonchildbearing potential (WONCBP) OR * Is a woman of childbearing potential (WOCBP) and agrees to use a contraceptive method that is highly effective, with a failure rate of \<1% during the study intervention period (to be effective before starting the intervention) and for at least 30 days after the last administration of study intervention. * A WOCBP must have a negative highly sensitive pregnancy test at screening (serum) and within 24 hours (urine or serum as required by local regulations) before the first administration of study intervention. * Lactating woman must interrupt breastfeeding and pump and discard breast milk during and for 20 days after last administration of study intervention. * Capable of giving signed informed consent as described in Appendix 1 of the protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. Note: For minor participants, a specific ICF must also be signed by the participant's legally authorized representative (LAR). Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Participant has diabetes other than autoimmune T1D that includes but is not limited to genetic forms of diabetes, maturity-onset diabetes of the young (MODY), diabetes secondary to medications or surgery and type 2 diabetes by judgement of the Investigator. * Participant has an active serious infection and/or fever ≥38.5°C (101.3°F) within the 48 hours prior to the first dose (except if localized skin infection), or has chronic, recurrent or opportunistic infectious disease. * At screening, participant has laboratory or clinical evidence of acute or clinically active infection with Epstein-Barr virus (EBV), cytomegalovirus (CMV). * At screening, participant has positive serology for human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV). * Participant has evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posterior anterior and lateral), and/or TB testing. Blood testing (eg, QuantiFERON® TB Gold test) is strongly preferred; if not available, any local approved TB test is allowed. * Has other autoimmune diseases, (eg, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, systemic lupus erythematosus etc), except clinically stable autoimmune thyroid disease, or controlled celiac disease (at discretion of Investigator). * Any clinically significant abnormality identified either in medical/surgical history or during screening evaluation (eg, physical examination, laboratory tests, vital signs), or any adverse event (AE) during screening period which, in the judgment of the investigator, would preclude safe completion of the study or constrains efficacy assessment. * Participant has recent or planned vaccinations as follows: * Live-attenuated (live) vaccines (eg, varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, and smallpox) within the 8 weeks before first dose of the investigational medicinal product (IMP) or planned/required administration during treatment or up to 26 weeks after last IMP administration in any treatment course * Inactivated or mRNA vaccines within 2 weeks before the first dose of IMP or planned required administration during treatment or up to 6 weeks after last IMP administration in any treatment course. * Current or prior use (within 30 days before screening) of any anti-hyperglycemic agents other than insulin * Past (within 30 days prior to screening) or current administration of any treatment that is known to cause a significant, ongoing change in the course of T1D or immunologic status, including but not limited to systemic corticosteroids (ie, oral, high doses of inhaled or injectable) with duration \>14 days, adrenocorticotropic hormone, verapamil). * Past systemic immunosuppression medicine or immune modulatory biologic therapy (such as monoclonal antibodies), within 3 months or 5 half-lifes (whichever is longer) prior to dosing. * Current or prior (within 30 days before screening) use of any medication known to significantly influence glucose tolerance (eg, atypical antipsychotics, diphenylhydantoin, niacin). * Participant has previously received teplizumab or other anti-CD3 treatment. * Other medications not compatible or interfering with IMP at discretion of Investigator. * Current enrollment OR past participation in another investigational study in which an investigational intervention (eg, drug, vaccine, invasive device) was administered within the last 8 weeks or 5 half-lifes, whichever is longer, prior to screening. * Participant has any of the following laboratory parameters, at screening prior to first dose: * Lymphocyte count: \<1000/µL, * Neutrophil count: \<1500/µL (\< 1000 /µL in participants with documented Duffy-null genotype), * Platelet count: \<150,000 platelets/µL, * Hemoglobin: \<10 g/dL, * Aspartate aminotransferase (AST) \>2.0 × upper limit of normal (ULN), * Alanine aminotransferase (ALT) \>2.0 × ULN, * Total bilirubin \>1.5 × ULN with the exception of participants with the diagnosis of Gilbert's syndrome who may be eligible provided they have no other causes leading to hyperbilirubinemia The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes mellitus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    197 sites in 19 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AM Diabetes & Endocrinology Center- Site Number : 8400004

    RECRUITING

    Bartlett, Tennessee, 38133, United States

  • AdventHealth Winter Park- Site Number : 8400033

    RECRUITING

    Winter Park, Florida, 32792, United States

  • Asheville Clinical Research- Site Number : 8400045

    RECRUITING

    Asheville, North Carolina, 28803, United States

  • Atlanta Diabetes Associates- Site Number : 8400036

    RECRUITING

    Atlanta, Georgia, 30318, United States

  • Barbara Davis Center for Childhood Diabetes- Site Number : 8400031

    RECRUITING

    Aurora, Colorado, 80045, United States

  • Baylor College of Medicine- Site Number : 8400057

    RECRUITING

    Houston, Texas, 77030, United States

  • Benaroya Research Institute at Virginia Mason- Site Number : 8400038

    RECRUITING

    Seattle, Washington, 98101, United States

  • C.S. Mott Children's Hospital- Site Number : 8400015

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Centro de Diabetes Curitiba- Site Number : 0760006

    RECRUITING

    Curitiba, Paraná, 80810-040, Brazil

  • Centro de Pesquisa Clínica de Marília - CPCLIM- Site Number : 0760002

    RECRUITING

    Marília, São Paulo, 17504-072, Brazil

  • Centro de Pesquisas Clínicas - São Paulo- Site Number : 0760011

    RECRUITING

    São Paulo, 01228-200, Brazil

  • Children's Healthcare of Atlanta - Egleston Hospital- Site Number : 8400065

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Children's Mercy Adelle Hall Campus- Site Number : 8400010

    RECRUITING

    Kansas City, Missouri, 64108, United States

  • Cincinnati Children's Hospital Medical Center- Site Number : 8400018

    RECRUITING

    Cincinnati, Ohio, 45229, United States

  • Columbia University Irving Medical Center- Site Number : 8400009

    RECRUITING

    New York, New York, 10032, United States

  • Encore Medical Research - Hollywood- Site Number : 8400061

    RECRUITING

    Hollywood, Florida, 33024, United States

  • Endocrine Associates of West Village- Site Number : 8400064

    RECRUITING

    New York, New York, 10001, United States

  • Hospital Israelita Albert Einstein- Site Number : 0760001

    RECRUITING

    São Paulo, 05651-901, Brazil

  • Hospital Universitario Clementino Fraga Filho- Site Number : 0760008

    RECRUITING

    Rio de Janeiro, 21941-913, Brazil

  • Hospital Universitario Walter Cantidio- Site Number : 0760009

    RECRUITING

    Fortaleza, Ceará, 60430-270, Brazil

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760012

    RECRUITING

    São Paulo, 05403-000, Brazil

  • IACT Health - Columbus - Talbotton Road- Site Number : 8400003

    RECRUITING

    Columbus, Georgia, 31904, United States

  • Investigational Site Number : 0320002

    RECRUITING

    Salta, 4400, Argentina

  • Investigational Site Number : 0320003

    RECRUITING

    San Miguel de Tucumán, Tucumán Province, 4000, Argentina

  • Investigational Site Number : 0320005

    RECRUITING

    Buenos Aires, 1419, Argentina

  • Investigational Site Number : 0320008

    RECRUITING

    Mar del Plata, Buenos Aires, 7600, Argentina

  • Investigational Site Number : 0320012

    RECRUITING

    Santa Fe, 3000, Argentina

  • Investigational Site Number : 0320013

    RECRUITING

    Córdoba, 5004, Argentina

  • Investigational Site Number : 0360001

    RECRUITING

    Brisbane, Queensland, 4101, Australia

  • Investigational Site Number : 0360002

    RECRUITING

    Perth, Western Australia, 6009, Australia

  • Investigational Site Number : 0360003

    RECRUITING

    Adelaide, South Australia, 5006, Australia

  • Investigational Site Number : 0560001

    RECRUITING

    Leuven, 3000, Belgium

  • Investigational Site Number : 0560002

    RECRUITING

    Jette, 1090, Belgium

  • Investigational Site Number : 0560004

    RECRUITING

    Namur, 5000, Belgium

  • Investigational Site Number : 0560005

    RECRUITING

    Brussels, 1020, Belgium

  • Investigational Site Number : 0560006

    RECRUITING

    Liège, 4000, Belgium

  • Investigational Site Number : 0560007

    RECRUITING

    Edegem, 2650, Belgium

  • Investigational Site Number : 0560008

    RECRUITING

    Leuven, 3000, Belgium

  • Investigational Site Number : 0560009

    RECRUITING

    Brussels, 1070, Belgium

  • Investigational Site Number : 1240002

    RECRUITING

    Halifax, Nova Scotia, B3H 2Y9, Canada

  • Investigational Site Number : 1240008

    RECRUITING

    Calgary, Alberta, T2N 4L7, Canada

  • Investigational Site Number : 1240009

    RECRUITING

    Vancouver, British Columbia, V5Z 1M9, Canada

  • Investigational Site Number : 1560001

    RECRUITING

    Changsha, 410011, China

  • Investigational Site Number : 1560002

    RECRUITING

    Wuhan, 430030, China

  • Investigational Site Number : 1560003

    RECRUITING

    Beijing, 100034, China

  • Investigational Site Number : 1560005

    RECRUITING

    Nanjing, 210008, China

  • Investigational Site Number : 1560007

    RECRUITING

    Guangzhou, 510120, China

  • Investigational Site Number : 1560009

    RECRUITING

    Changchun, 130041, China

  • Investigational Site Number : 1560010

    RECRUITING

    Harbin, 150001, China

  • Investigational Site Number : 1560012

    RECRUITING

    Hangzhou, 310014, China

  • Investigational Site Number : 1560013

    RECRUITING

    Shenyang, 110004, China

  • Investigational Site Number : 1560014

    RECRUITING

    Hangzhou, 310009, China

  • Investigational Site Number : 1560016

    RECRUITING

    Luoyang, 471003, China

  • Investigational Site Number : 1560018

    RECRUITING

    Nanchang, 330006, China

  • Investigational Site Number : 1560019

    RECRUITING

    Tianjin, 300052, China

  • Investigational Site Number : 1560026

    RECRUITING

    Hohhot, 010050, China

  • Investigational Site Number : 1560027

    RECRUITING

    Zhenjiang, 212000, China

  • Investigational Site Number : 1560031

    RECRUITING

    Shanghai, 200032, China

  • Investigational Site Number : 1560032

    RECRUITING

    Shanghai, 200040, China

  • Investigational Site Number : 1560033

    RECRUITING

    Beijing, 100045, China

  • Investigational Site Number : 1560034

    RECRUITING

    Nanjing, 210008, China

  • Investigational Site Number : 1560035

    RECRUITING

    Beijing, 100020, China

  • Investigational Site Number : 1560037

    RECRUITING

    Guangzhou, 510620, China

  • Investigational Site Number : 1560038

    RECRUITING

    Zhengzhou, 450018, China

  • Investigational Site Number : 1560039

    RECRUITING

    Wuhan, 430010, China

  • Investigational Site Number : 1560040

    RECRUITING

    Hangzhou, 310003, China

  • Investigational Site Number : 1560041

    RECRUITING

    Wuxi, 214023, China

  • Investigational Site Number : 1560042

    RECRUITING

    Chengdu, 610091, China

  • Investigational Site Number : 1560043

    RECRUITING

    Nanchang, 330038, China

  • Investigational Site Number : 1560045

    RECRUITING

    Shenzhen, 518026, China

  • Investigational Site Number : 1560050

    RECRUITING

    Pingxiang, 337055, China

  • Investigational Site Number : 1560054

    RECRUITING

    Nanjing, 210029, China

  • Investigational Site Number : 1560055

    RECRUITING

    Chengdu, 610072, China

  • Investigational Site Number : 1560056

    RECRUITING

    Lanzhou, 730000, China

  • Investigational Site Number : 1560059

    RECRUITING

    Jinan, 250001, China

  • Investigational Site Number : 1560060

    RECRUITING

    Yueyang, 414000, China

  • Investigational Site Number : 2030001

    RECRUITING

    Prague, 150 06, Czechia

  • Investigational Site Number : 2030003

    RECRUITING

    Prague, 140 21, Czechia

  • Investigational Site Number : 2030004

    RECRUITING

    Prague, 128 08, Czechia

  • Investigational Site Number : 2500001

    RECRUITING

    Paris, 75015, France

  • Investigational Site Number : 2500002

    RECRUITING

    Paris, 75010, France

  • Investigational Site Number : 2500004

    RECRUITING

    Bron, 69500, France

  • Investigational Site Number : 2500005

    RECRUITING

    Pau, 64000, France

  • Investigational Site Number : 2500007

    RECRUITING

    Strasbourg, 67000, France

  • Investigational Site Number : 2500008

    RECRUITING

    Paris, 75013, France

  • Investigational Site Number : 2500009

    RECRUITING

    Paris, 75019, France

  • Investigational Site Number : 2500010

    RECRUITING

    La Tronche, 38700, France

  • Investigational Site Number : 2500011

    RECRUITING

    Lille, 59037, France

  • Investigational Site Number : 2760001

    RECRUITING

    Ulm, 89081, Germany

  • Investigational Site Number : 2760002

    RECRUITING

    Augsburg, 86156, Germany

  • Investigational Site Number : 2760003

    RECRUITING

    Freiburg im Breisgau, 79106, Germany

  • Investigational Site Number : 2760005

    RECRUITING

    Hanover, 30173, Germany

  • Investigational Site Number : 2760006

    RECRUITING

    Leipzig, 04103, Germany

  • Investigational Site Number : 2760007

    RECRUITING

    Dresden, 01307, Germany

  • Investigational Site Number : 2760008

    RECRUITING

    Bielefeld, 33617, Germany

  • Investigational Site Number : 2760010

    RECRUITING

    Munich, 81675, Germany

  • Investigational Site Number : 2760012

    RECRUITING

    Frankfurt, 60590, Germany

  • Investigational Site Number : 3000001

    RECRUITING

    Athens, 115 28, Greece

  • Investigational Site Number : 3000003

    RECRUITING

    Thessaloniki, 546 42, Greece

  • Investigational Site Number : 3000004

    RECRUITING

    Athens, 124 62, Greece

  • Investigational Site Number : 3000005

    RECRUITING

    Athens, 115 27, Greece

  • Investigational Site Number : 3760001

    RECRUITING

    Ramat Gan, 5262100, Israel

  • Investigational Site Number : 3760002

    RECRUITING

    Petah Tikva, 4920235, Israel

  • Investigational Site Number : 3760003

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Investigational Site Number : 3760004

    RECRUITING

    Tel Aviv, 6423906, Israel

  • Investigational Site Number : 3760005

    RECRUITING

    Jerusalem, 9112001, Israel

  • Investigational Site Number : 3760006

    RECRUITING

    Rehovot, 7610001, Israel

  • Investigational Site Number : 3800001

    RECRUITING

    Florence, Firenze, 50139, Italy

  • Investigational Site Number : 3800002

    RECRUITING

    Verona, 37126, Italy

  • Investigational Site Number : 3800003

    RECRUITING

    Rome, Roma, 00165, Italy

  • Investigational Site Number : 3800004

    RECRUITING

    Bologna, 40138, Italy

  • Investigational Site Number : 3800005

    RECRUITING

    Milan, Milano, 20154, Italy

  • Investigational Site Number : 3800008

    RECRUITING

    Genoa, Genova, 16147, Italy

  • Investigational Site Number : 3800010

    RECRUITING

    Turin, Torino, 10126, Italy

  • Investigational Site Number : 3800011

    RECRUITING

    Milan, Milano, 20157, Italy

  • Investigational Site Number : 3800012

    RECRUITING

    Rome, Roma, 00161, Italy

  • Investigational Site Number : 3800013

    RECRUITING

    Siena, 53100, Italy

  • Investigational Site Number : 3800014

    RECRUITING

    Messina, 98125, Italy

  • Investigational Site Number : 3800015

    RECRUITING

    Novara, 28100, Italy

  • Investigational Site Number : 3920001

    RECRUITING

    Sapporo, Hokkaido, 060-8543, Japan

  • Investigational Site Number : 3920002

    RECRUITING

    Osaka, 545-8586, Japan

  • Investigational Site Number : 3920003

    RECRUITING

    Kobe, Hyōgo, 650-0017, Japan

  • Investigational Site Number : 3920005

    RECRUITING

    Fukuoka, 813-0017, Japan

  • Investigational Site Number : 3920006

    RECRUITING

    Niigata, 951-8520, Japan

  • Investigational Site Number : 3920007

    RECRUITING

    Koshigaya, Saitama, 343-0845, Japan

  • Investigational Site Number : 3920010

    RECRUITING

    Moriyama, Shiga, 524-8524, Japan

  • Investigational Site Number : 3920011

    RECRUITING

    Azumino, Nagano, 399-8288, Japan

  • Investigational Site Number : 3920012

    RECRUITING

    Shizuoka, 420-0953, Japan

  • Investigational Site Number : 3920013

    RECRUITING

    Tokyo, 101-8309, Japan

  • Investigational Site Number : 3920014

    RECRUITING

    Tokyo, 105-8461, Japan

  • Investigational Site Number : 3920015

    RECRUITING

    Kyoto, 606-8507, Japan

  • Investigational Site Number : 3920016

    RECRUITING

    Tokyo, 162-8655, Japan

  • Investigational Site Number : 3920017

    RECRUITING

    Nara, 630-8581, Japan

  • Investigational Site Number : 3920020

    RECRUITING

    Nagoya, Aichi-ken, 453-8511, Japan

  • Investigational Site Number : 3920021

    RECRUITING

    Tokyo, 113-0033, Japan

  • Investigational Site Number : 3920022

    RECRUITING

    Chiba, 266-0007, Japan

  • Investigational Site Number : 3920023

    RECRUITING

    Yokohama, Kanagawa, 232-0024, Japan

  • Investigational Site Number : 3920025

    RECRUITING

    Iruma, Saitama, 350-0495, Japan

  • Investigational Site Number : 3920026

    RECRUITING

    Tokyo, 157-8535, Japan

  • Investigational Site Number : 5280001

    RECRUITING

    Rotterdam, 3011 TA, Netherlands

  • Investigational Site Number : 5280002

    RECRUITING

    Leiden, 2333 ZA, Netherlands

  • Investigational Site Number : 5280003

    RECRUITING

    Amersfoort, 3813 TZ, Netherlands

  • Investigational Site Number : 6160001

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-117, Poland

  • Investigational Site Number : 6160003

    RECRUITING

    Warsaw, Masovian Voivodeship, 04-746, Poland

  • Investigational Site Number : 6160004

    RECRUITING

    Lublin, Lublin Voivodeship, 20-601, Poland

  • Investigational Site Number : 6160005

    RECRUITING

    Lodz, Lódzkie, 92-213, Poland

  • Investigational Site Number : 6160006

    RECRUITING

    Bialystok, 15-274, Poland

  • Investigational Site Number : 6160008

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-097, Poland

  • Investigational Site Number : 6420001

    RECRUITING

    Bacau, 600164, Romania

  • Investigational Site Number : 6420003

    RECRUITING

    Iași, 700514, Romania

  • Investigational Site Number : 7240001

    RECRUITING

    Seville, Andalusia, 41013, Spain

  • Investigational Site Number : 7240003

    RECRUITING

    Sabadell, 08208, Spain

  • Investigational Site Number : 7240004

    RECRUITING

    Esplugues de Llobregat, Barcelona [Barcelona], 08950, Spain

  • Investigational Site Number : 7240006

    RECRUITING

    Madrid, 28007, Spain

  • Investigational Site Number : 7240007

    RECRUITING

    Madrid, Madrid, Comunidad de, 28046, Spain

  • Investigational Site Number : 7240009

    RECRUITING

    Madrid, Madrid, Comunidad de, 28034, Spain

  • Investigational Site Number : 7240010

    RECRUITING

    Madrid, 28009, Spain

  • Investigational Site Number : 7240011

    RECRUITING

    Madrid, Madrid, Comunidad de, 28040, Spain

  • Investigational Site Number : 7240012

    RECRUITING

    Santiago de Compostela, A Coruña [La Coruña], 15706, Spain

  • Investigational Site Number : 7240014

    RECRUITING

    Vigo, Pontevedra [Pontevedra], 36312, Spain

  • Investigational Site Number : 7240015

    RECRUITING

    Palma, 07120, Spain

  • Investigational Site Number : 7240016

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Investigational Site Number : 7240017

    RECRUITING

    Barcelona, Catalunya [Cataluña], 08035, Spain

  • Investigational Site Number : 7240019

    RECRUITING

    San Cristóbal de La Laguna, Santa Cruz De Tenerife, 38320, Spain

  • Investigational Site Number : 7240020

    RECRUITING

    Bizkaia, Basque Country, 48903, Spain

  • Investigational Site Number : 7240021

    RECRUITING

    Seville, Sevilla, 41009, Spain

  • Investigational Site Number : 7240022

    RECRUITING

    Málaga, 29010, Spain

  • Investigational Site Number : 7240023

    RECRUITING

    Alcalá de Henares, Madrid, 28805, Spain

  • Investigational Site Number : 8260001

    RECRUITING

    Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom

  • Investigational Site Number : 8260002

    RECRUITING

    Glasgow, Glasgow City, G51 4TF, United Kingdom

  • Investigational Site Number : 8260003

    RECRUITING

    Sheffield, S10 2TH, United Kingdom

  • Investigational Site Number : 8260004

    RECRUITING

    Dundee, Dundee City, DD1 9SY, United Kingdom

  • Investigational Site Number : 8260005

    RECRUITING

    Leeds, LS9 7TF, United Kingdom

  • Investigational Site Number : 8260006

    RECRUITING

    Guildford, Surrey, GU2 7XX, United Kingdom

  • Investigational Site Number : 8260007

    RECRUITING

    London, London, City of, SE5 9RL, United Kingdom

  • Investigational Site Number : 8260009

    RECRUITING

    London, England, E1 1BB, United Kingdom

  • Investigational Site Number : 8260010

    RECRUITING

    Reading, RG1 5AN, United Kingdom

  • Investigational Site Number : 8260011

    RECRUITING

    Bath, Somerset, BA1 3NG, United Kingdom

  • Investigational Site Number : 8260012

    RECRUITING

    London, England, SW10 9NH, United Kingdom

  • Mayo Clinic in Rochester - Minnesota- Site Number : 8400019

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • MultiCare Mary Bridge Children's Health Center- Site Number : 8400037

    RECRUITING

    Tacoma, Washington, 98405, United States

  • Nemours Children's Speciality Care- Jacksonville- Site Number : 8400040

    RECRUITING

    Jacksonville, Florida, 32207, United States

  • Norton Children's Research Institute - Wendy Novak Diabetes Institute- Site Number : 8400016

    RECRUITING

    Louisville, Kentucky, 40202, United States

  • Park Nicollet Institute - Oncology Research- Site Number : 8400059

    RECRUITING

    Saint Louis Park, Minnesota, 55426, United States

  • Rocky Mountain Clinical Research - Idaho Falls- Site Number : 8400001

    RECRUITING

    Idaho Falls, Idaho, 83404, United States

  • Scottsdale Clinical Trials- Site Number : 8400044

    RECRUITING

    Scottsdale, Arizona, 85260, United States

  • St. Luke's Children's Hospital- Site Number : 8400014

    RECRUITING

    Boise, Idaho, 83712, United States

  • The Children's Hospital of Philadelphia- Site Number : 8400039

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • The Ohio State University- Site Number : 8400051

    RECRUITING

    Columbus, Ohio, 43210, United States

  • UNC Children's Hospital- Site Number : 8400034

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

  • University At Buffalo - Jacobs School Of Medicine- Site Number : 8400006

    RECRUITING

    Buffalo, New York, 14203, United States

  • University of California San Francisco - Mission Bay- Site Number : 8400011

    RECRUITING

    San Francisco, California, 94158, United States

  • University of Florida College of Medicine- Site Number : 8400054

    RECRUITING

    Gainesville, Florida, 32610, United States

  • University of South Florida- Site Number : 8400013

    RECRUITING

    Tampa, Florida, 33612, United States

  • University of Utah Health Hospital- Site Number : 8400052

    RECRUITING

    Salt Lake City, Utah, 84132, United States

  • Uva Children's Battle Building- Site Number : 8400060

    RECRUITING

    Charlottesville, Virginia, 22903, United States

  • Yale University School of Medicine- Site Number : 8400005

    RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.